Surgical management of breast cancer in BRCA-mutation carriers: A systematic review and meta-analysis

Breast Cancer Research and Treatment

Volumn 144, Issue 3, 2014, Pages 443-455

  Valachis, Antonis ^a,b   Nearchou, Andreas D ^a   Lind, Pehr ^a,c  

^a Department of Oncology Mälarsjukhuset ^*  (Sweden)

^b UPPSALA UNIVERSITY   (Sweden)

^c KAROLINSKA INSTITUTE   (Sweden)

Author keywords

BRCA; Breast cancer; Breast conserving therapy; Meta analysis

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; TAMOXIFEN;

AGE; BREAST CANCER; BREAST CANCER SPECIFIC SURVIVAL; BREAST CONSERVING THERAPY; CANCER ADJUVANT THERAPY; CANCER GRADING; CANCER RECURRENCE; CANCER RISK; CANCER SPECIFIC SURVIVAL; CANCER THERAPY; CASE CONTROL STUDY; COHORT ANALYSIS; CONTRALATERAL BREAST CANCER; DISEASE CARRIER; FOLLOW UP; GENE MUTATION; HUMAN; INTERMETHOD COMPARISON; IPSILATERAL BREAST RECURRENCE; MASTECTOMY; MULTIVARIATE ANALYSIS; OBSERVATIONAL STUDY; ONCOGENE; ONCOGENE BRCA; OVARIECTOMY; OVERALL SURVIVAL; PRIORITY JOURNAL; QUALITATIVE ANALYSIS; RETROSPECTIVE STUDY; REVIEW; RISK FACTOR; RISK REDUCTION; SAFETY; SYSTEMATIC REVIEW; TUMOR SUPPRESSOR GENE;

BREAST NEOPLASMS; CASE-CONTROL STUDIES; FEMALE; GENES, BRCA1; GENES, BRCA2; HETEROZYGOTE; HUMANS; MASTECTOMY; MASTECTOMY, SEGMENTAL; MUTATION; NEOPLASM RECURRENCE, LOCAL; ODDS RATIO; RISK FACTORS;

EID: 84899476341     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-014-2890-1     Document Type: Review

References (44)

1. Begg CB, Haile RW, Borg A et al (2008) Variation of breast cancer risk among BRCA1/2 carriers. JAMA 299:194-201
2. Chen S, Parmigiani G (2007) Meta-analysis of BRCA1 and BRCA2 penetrance. J Clin Oncol 25:1329-1333 (Pubitemid 46706879)
3. Clarke M, Collins R, Darby S, Early Breast Cancer Trialists' Collaborative Group (EBCTCG) et al (2005) Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet 366:2087-2106 (Pubitemid 41797643)
4. Brekelmans CT, Tilanus-Linthorst MM, Seynaeve C et al (2007) Tumour characteristics, survival and prognostic factors of hereditary breast cancer from BRCA2-, BRCA1- and non- BRCA1/2 families as compared to sporadic breast cancer cases. Eur J Cancer 43:867-876 (Pubitemid 46366688)
5. Chappuis PO, Kapusta L, Bé gin LR et al (2000) Germline BRCA1/2 mutations and p27(Kip1) protein levels independently predict outcome after breast cancer. J Clin Oncol 18:4045-4052 (Pubitemid 32038396)
6. Eccles D, Simmonds P, Goddard J et al (2001) Familial breast cancer: an investigation into the outcome of treatment for early stage disease. Fam Cancer 1:65-72 (Pubitemid 35221517)
7. El-Tamer M, Russo D, Troxel A et al (2004) Survival and recurrence after breast cancer in BRCA1/2 mutation carriers. Ann Surg Oncol 11:157-164 (Pubitemid 40486790)
8. Garcia-Etienne CA, Barile M, Gentilini OD et al (2009) Breastconserving surgery in BRCA1/2 mutation carriers: are we approaching an answer? Ann Surg Oncol 16:3380-3387
9. Haffty BG, Harrold E, Khan AJ et al (2002) Outcome of conservatively managed early-onset breast cancer by BRCA1/2 status. Lancet 359:1471-1477 (Pubitemid 34457765)
10. Kirova YM, Savignoni A, Sigal-Zafrani B et al (2010) Is the breast-conserving treatment with radiotherapy appropriate in BRCA1/2 mutation carriers? Long-term results and review of the literature. Breast Cancer Res Treat 120:119-126
11. Metcalfe K, Gershman S, Lynch HT et al (2011) Predictors of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers. Br J Cancer 104:1384-1392
12. Metcalfe K, Lynch HT, Ghadirian P et al (2011) Risk of ipsilateral breast cancer in BRCA1 and BRCA2 mutation carriers. Breast Cancer Res Treat 127:287-296
13. Pierce LJ, Phillips KA, Griffith KA et al (2010) Local therapy in BRCA1 and BRCA2 mutation carriers with operable breast cancer: comparison of breast conservation and mastectomy. Breast Cancer Res Treat 121:389-398
14. Pierce LJ, Levin AM, Rebbeck TR et al (2006) Ten-year multi-institutional results of breast-conserving surgery and radiotherapy in BRCA1/2-associated stage I/II breast cancer. J Clin Oncol 24:2437-2443 (Pubitemid 46630619)
15. Robson ME, Chappuis PO, Satagopan J et al (2004) A combined analysis of outcome following breast cancer: differences in survival based on BRCA1/BRCA2 mutation status and administration of adjuvant treatment. Breast Cancer Res 6:R8-R17
16. Stoppa-Lyonnet D, Ansquer Y, Dreyfus H et al (2000) Familial invasive breast cancers: worse outcome related to BRCA1 mutations. J Clin Oncol 18:4053-4059 (Pubitemid 32038397)
17. Stroup DF, Berlin JA, Morton SC et al (2000) Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis of observational studies in epidemiology (MOOSE) group. JAMA 283:2008-2012 (Pubitemid 30214957)
18. Viswanathan M, Berkman ND (2012) Development of the RTI item bank on risk of bias and precision of observational studies. J Clin Epidemiol 65:163-178
19. Huang E, Buchholz TA, Meric F et al (2002) Classifying local disease recurrences after breast conservation therapy based on location and histology: new primary tumors have more favorable outcomes than true local disease recurrences. Cancer 95:2059-2067 (Pubitemid 35253366)
20. Panet-Raymond V, Truong PT, McDonald RE, Alexander C, Ross L, Ryhorchuk A, Watson PH (2011) True recurrence versus new primary: an analysis of ipsilateral breast tumor recurrences after breast-conserving therapy. Int J Radiat Oncol Biol Phys 81:409-417
21. Smith TE, Lee D, Turner BC, Carter D, Haffty BG (2000) True recurrence vs. new primary ipsilateral breast tumor relapse: an analysis of clinical and pathologic differences and their implications in natural history, prognoses, and therapeutic management. Int J Radiat Oncol Biol Phys 48:1281-1289
22. Pierce LJ, Strawderman M, Narod SA et al (2000) Effect of radiotherapy after breast-conserving treatment in women with breast cancer and germline BRCA1/2 mutations. J Clin Oncol 18:3360-3369
23. Robson M, Gilewski T, Haas B et al (1998) BRCA-associated breast cancer in young women. J Clin Oncol 16:1642-1649
24. Graeser MK, Engel C, Rhiem K et al (2009) Contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers. J Clin Oncol 27:5887-5892
25. Mavaddat N, Peock S, Frost D, on behalf of EMBRACE et al (2013) Cancer risks for BRCA1 and BRCA2 mutation carriers: results from prospective analysis of EMBRACE. J Natl Cancer Inst 105:812-822
26. Robson M, Svahn T, McCormick B, Borgen P, Hudis CA, Norton L, Offit K (2005) Appropriateness of breast-conserving treatment of breast carcinoma in women with germline mutations in BRCA1 or BRCA2: a clinic-based series. Cancer 103:44-51 (Pubitemid 39665455)
27. van der Kolk DM, de Bock GH, Leegte BK, Schaapveld M, Mourits MJ, de Vries J, van der Hout AH, Oosterwijk JC (2010) Penetrance of breast cancer, ovarian cancer and contralateral breast cancer in BRCA1 and BRCA2 families: high cancer incidence at older age. Breast Cancer Res Treat 124:643-651
28. Gronwald J, Tung N, Foulkes WD, Hereditary Breast Cancer Clinical Study Group et al (2006) Tamoxifen and contralateral breast cancer in BRCA1 and BRCA2 carriers: an update. Int J Cancer 118:2281-2284
29. Malone KE, Begg CB, Haile RW et al (2010) Population-based study of the risk of second primary contralateral breast cancer associated with carrying a mutation in BRCA1 or BRCA2. J Clin Oncol 28:2404-2410
30. Reding KW, Bernstein JL, Langholz BM, WECARE Collaborative Study Group (2010) Adjuvant systemic therapy for breast cancer in BRCA1/BRCA2 mutation carriers in a population-based study of risk of contralateral breast cancer. Breast Cancer Res Treat 123:491-498
31. Verhoog LC, Brekelmans CT, Seynaeve C, Meijers-Heijboer EJ, Klijn JG (2000) Contralateral breast cancer risk is influenced by the age at onset in BRCA1-associated breast cancer. Br J Cancer 83:384-386 (Pubitemid 30453580)
32. van Sprundel TC, Schmidt MK, Rookus MA, Brohet R, van Asperen CJ, Rutgers EJ, Van't Veer LJ, Tollenaar RA (2005) Risk reduction of contralateral breast cancer and survival after contralateral prophylactic mastectomy in BRCA1 or BRCA2 mutation carriers. Br J Cancer 93:287-292 (Pubitemid 43080030)
33. Goodwin PJ, Phillips KA, West DW et al (2012) Breast cancer prognosis in BRCA1 and BRCA2 mutation carriers: an international prospective breast cancer family registry population-based cohort study. J Clin Oncol 30:19-26
34. Rennert G, Bisland-Naggan S, Barnett-Griness O, Bar-Joseph N, Zhang S, Rennert HS, Narod SA (2007) Clinical outcomes of breast cancer in carriers of BRCA1 and BRCA2 mutations. N Engl J Med 357:115-123 (Pubitemid 47057729)
35. Lostumbo L, Carbine NE, Wallace J (2010) Prophylactic mastectomy for the prevention of breast cancer. Cochrane Database Syst Rev 11:CD002748
36. Heemskerk-Gerritsen B, Hooning M, van Asperen CJ et al (2013) Efficacy of risk-reducing mastectomy (RRM) on overall survival (OS) in BRCA1/2-associated breast cancer (BC) patients. J Clin Oncol (Meeting Abstracts) 31(15 suppl):1502
37. Fourquet A, Stoppa-Lyonnet D, Kirova YM, Sigal-Zafrani B, Asselain B, Institut Curie Breast Cancer Study Group, Institut Curie Breast Ovary Cancer Risk Study Group (2009) Familial breast cancer: clinical response to induction chemotherapy or radiotherapy related to BRCA1/2 mutations status. Am J Clin Oncol 32:127-131
38. Kriege M, Seynaeve C, Meijers-Heijboer H et al (2009) Sensitivity to first-line chemotherapy for metastatic breast cancer in BRCA1 and BRCA2 mutation carriers. J Clin Oncol 27: 3764-3771
39. Brandberg Y, Sandelin K, Erikson S et al (2008) Psychological reactions, quality of life, and body image after bilateral prophylactic mastectomy in women at high risk for breast cancer: a prospective 1-year follow-up study. J Clin Oncol 26:3943-3949
40. Tercyak KP, Peshkin BN, Brogan BM et al (2007) Quality of life after contralateral prophylactic mastectomy in newly diagnosed high-risk breast cancer patients who underwent BRCA1/2 gene testing. J Clin Oncol 25:285-291 (Pubitemid 350003016)
41. Unukovych D, Sandelin K, Liljegren A, Arver B, Wickman M, Johansson H, Brandberg Y (2012) Contralateral prophylactic mastectomy in breast cancer patients with a family history: a prospective 2-years follow-up study of health related quality of life, sexuality and body image. Eur J Cancer 48:3150-3156
42. Frost MH, Slezak JM, Tran NV et al (2005) Satisfaction after contralateral prophylactic mastectomy: the significance of mastectomy type, reconstructive complications, and body appearance. J Clin Oncol 23:7849-7856 (Pubitemid 46657383)
43. Da Silva L, Lakhani SR (2010) Pathology of hereditary breast cancer. Mod Pathol Suppl 2:S46-S51
44. Rebbeck TR, Kauff ND, Domchek SM (2009) Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers. J Natl Cancer Inst 101:80-87